MARKET

DRMA

DRMA

Dermata Therapeutics Inc
NASDAQ
0.7290
+0.0190
+2.68%
After Hours: 0.7450 +0.016 +2.19% 18:52 04/17 EDT
OPEN
0.7200
PREV CLOSE
0.7100
HIGH
0.7300
LOW
0.7000
VOLUME
44.85K
TURNOVER
--
52 WEEK HIGH
6.17
52 WEEK LOW
0.7000
MARKET CAP
3.96M
P/E (TTM)
-0.0908
1D
5D
1M
3M
1Y
5Y
1D
Optimistic Buy Rating for Dermata Therapeutics Driven by Promising Phase 3 Trial Results and Strong Financial Position
TipRanks · 3d ago
Dermata Therapeutics files to sell 10.01M shares of common stock for holders
TipRanks · 4d ago
Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference At 4 Weeks
Benzinga · 5d ago
DERMATA THERAPEUTICS INC - ANNOUNCES TOPLINE RESULTS FROM PHASE 3 TRIAL OF XYNGARI - SEC FILING
Reuters · 5d ago
Weekly Report: what happened at DRMA last week (0407-0411)?
Weekly Report · 6d ago
Weekly Report: what happened at DRMA last week (0331-0404)?
Weekly Report · 04/07 10:18
Dermata Therapeutics, Inc. (DRMA) Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024
Press release · 04/07 07:40
Weekly Report: what happened at DRMA last week (0324-0328)?
Weekly Report · 03/31 10:24
More
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.

Webull offers Dermata Therapeutics Inc stock information, including NASDAQ: DRMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRMA stock methods without spending real money on the virtual paper trading platform.